Navigation Links
NexGen Biofuels Ltd. (Nasdaq: NXGN) Announces Receipt of Nasdaq Delisting Determination
Date:2/27/2008

NEW YORK, February 27 /PRNewswire-FirstCall/ -- NexGen Biofuels Ltd. (f/k/a Healthcare Technologies Ltd.) (the "Company") announced today that on February 26, 2008, the Company received a letter from the Nasdaq Listing Qualification Panel, informing the Company that the Panel had determined to delist the Company's ordinary shares from The Nasdaq Stock Market following a determination by the Staff of the Nasdaq Listing Qualifications Department that the Company had failed to meet the Nasdaq listing standards for a reverse merger in connection with the Company's Plan of Arrangement with NexGen Biofuels Inc. Nasdaq will suspend trading of the Company's ordinary shares effective at the open of business on Thursday, February 28, 2008.

The Company believes that, following the recent filing of a Form 211 by a market maker, its ordinary shares will be eligible for trading on the OTC Bulletin Board.

For more information on NexGen Biofuels, Inc., visit http://www.nexgenbiofuels.net.

Safe harbor: This press release contains certain forward looking statements within the meaning of section 27a of the securities act of 1933 and section 21e of the securities exchange act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement made by or on behalf of healthcare technologies ltd. Readers are referred to the documents filed by the company with the securities and exchange commission, specifically the form 8-k/a filed on February 12, 2008 that identifies important risks which could cause actual results to differ from those contained in the forward looking statements.

Contact: Eran Rotem CFO, +972-3-9277232


'/>"/>
SOURCE NexGen Biofuels Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Healthcare Technologies Ltd. Announces the Change of its Name to "NexGen Biofuels Ltd"
2. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
3. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
6. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
7. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
8. Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark.
9. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Fourth Quarter and Year End 2007 Earnings and 2008 Guidance Conference Call on the Web
10. Healthcare Technologies Ltd. (NASDAQ: HCTL) Announces Extension of Letters of Intent to Acquire Majority Interest in Two Ethanol Plants
11. HealthCare Technologies Ltd. (NASDAQ: HCTL) Announces Receipt of NASDAQ Delisting Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today ... 30, 2015, corporate highlights, and near-term milestones.  The ... at www.sedar.com ,  www.edgar.com and ... expects to launch its RCS-01 treatment for aging ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... opportunity for venture capital funds, investment firms and animal health companies to hear ... have raised $160 million. Several have also received licensing agreements or distribution contracts. ...
(Date:8/27/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, ... Company Limited (Biohaven), announced today that dosing has ... a glutamate modulating agent. Biohaven filed an investigational ... clearance from the U.S. Food and Drug Administration ... 54% equity interest in Biohaven, a private company. ...
(Date:8/27/2015)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced its ... Biorem,s complete second quarter financial statements and MD&A have been filed ... earnings per shareThree-months ended , Six -months endedJune 30 , June ... , 2014 Revenue , 4,709 , 2,459 ... 1,656 , 56 , 3,188 ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
... , , , ... Over the past decade, many organisms have been the,subject of large-scale genome projects, ... analysis. Knowledge of tissues and cells,that express particular genes is key to understanding,gene ... , , Microarrays and similar high-throughput gene ...
... , , , ... , , Choose Shrimp Alkaline Phosphatase,for ... , , , ... Phosphatase.,Avoid phenol:chloroform extractions; after dephosphorylation,inactivate Shrimp Alkaline Phosphatase completely,and irreversibly by heating at ...
... , , , , ... larger pack sizes,of PCR-Grade Nucleotides. These larger pack sizes,combine the best available quality with attractive pricing. ... , Single dNTPs , , ... are now available in 500-mol pack sizes.,The Deoxynucleoside Triphosphate Set, containing all four dNTPs (dATP, dCTP, ...
Cached Biology Technology:The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 2The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 3The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 4The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 5The DIG System Nonradioactive Automated,High-Throughput In Situ Hybridization:,a Powerful Tool for Functional Genomics Research 6PCR-Grade Nucleotides,Larger Pack Sizes Now Available 2
(Date:8/6/2015)... Germany , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking ... Epson,s Moverio BT-200 see-through head mounted display and on ... unprecedented quality and efficiency is brought to personalized visualization ... the first time, professionals and researchers can integrate gaze, ...
(Date:8/5/2015)... , August 5, 2015 ... & Access Management Market by Software, Services, Vertical (BFSI, Airport, ... & Geography - Global Forecast to 2020", published by ... Management Market globally into various segments. The global PIAM ... 2014 to $546.2 Million by 2019, at a CAGR ...
(Date:8/5/2015)... 5, 2015 The biosensors market is proving ... penetration into newer sectors, and development of devices resulting ... space has seen the entry of multiple participants each ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... of the Global Biosensors Market ( http://www.frost.com/nee9 ), ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... in The Netherlands have developed a technique for generating atom ... so-called super atoms (clusters of 13 silver atoms, for example) ... opened up a whole new branch of chemistry. A full ... Delft magazine Delft Outlook . If a ...
... 1, 2008) Recipe to recover more quickly from exercise: ... or six cups of strong coffee. Glycogen, the ... rapidly when athletes ingest both carbohydrate and caffeine following ... the Journal of Applied Physiology shows. Athletes ...
... CHICAGO The July 2008 issue of the Journal of ... may find of interest. Below is a summary of some of ... copy of a Journal article, e-mail media@eatright.org . ... ways to manage their weight are often advised to eat slowly, ...
Cached Biology News:Super atoms turn the periodic table upside down 2Post-exercise caffeine helps muscles refuel 2Post-exercise caffeine helps muscles refuel 3Post-exercise caffeine helps muscles refuel 4Highlights from the July 2008 Journal of the American Dietetic Association 2
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
B3GALT2 Immunogen: B3GALT2 (NP_003774, 324 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... ( Abpromise for all tested applications). ... KLH derived from within residues 500 to the ... acid sequence is proprietary) (Peptide ... Entrez Gene ID: 51043 ...
Rabbit polyclonal to SUR1 ( Abpromise for all tested applications). Antigen: Synthetic peptide Entrez Gene ID: 6833 Swiss Protein ID: Q09428...
Biology Products: